SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000891293-23-000015
Filing Date
2023-05-15
Accepted
2023-05-15 16:14:59
Documents
45
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ctic-20230331.htm   iXBRL 10-Q 800884
2 EX-10.1 ex101-amendmentno2toemploy.htm EX-10.1 11001
3 EX-10.2 ex102-amendmentno2tosevera.htm EX-10.2 14436
4 EX-31.1 ex311-ceo302q1fy23.htm EX-31.1 11334
5 EX-31.2 ex312-cfo302q1fy23.htm EX-31.2 12202
6 EX-32 ex32-ceocfo906q1fy23.htm EX-32 11647
  Complete submission text file 0000891293-23-000015.txt   3807959

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20230331.xsd EX-101.SCH 26687
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctic-20230331_cal.xml EX-101.CAL 44332
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctic-20230331_def.xml EX-101.DEF 147956
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20230331_lab.xml EX-101.LAB 344812
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20230331_pre.xml EX-101.PRE 213798
39 EXTRACTED XBRL INSTANCE DOCUMENT ctic-20230331_htm.xml XML 441474
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-28386 | Film No.: 23922471
SIC: 2834 Pharmaceutical Preparations